Cytokine trajectory over time in men and women with HIV on long-term antiretroviral therapy

被引:0
|
作者
Vanpouille, Christophe [1 ]
Wells, Alan [2 ]
Degruttola, Victor [3 ]
Lynch, Miranda [4 ]
Zhang, Xinlian [3 ]
Fitzgerald, Wendy [1 ]
Tu, Xin [3 ]
Chaillon, Antoine [2 ]
Landay, Alan [5 ]
Weber, Kathleen M. [6 ]
Scully, Eileen [7 ]
Karn, Jonathan [8 ]
Gianella, Sara [2 ]
机构
[1] NIH, Eunice Kennedy Shriver Natl Inst Child Hlth & Huma, Bethesda, MD USA
[2] Dept Med, Div Infect Dis & Global Publ Hlth, La Jolla, CA USA
[3] Univ Calif San Diego, Herbert Wertheim Sch Publ Hlth & Longev Sci, Div Biostat, La Jolla, CA USA
[4] Hauptman Woodward Med Res Inst, Buffalo, NY USA
[5] Univ Texas Med Branch, Dept Internal Med, Galveston, TX USA
[6] Hektoen Inst Med, Chicago, IL USA
[7] Johns Hopkins Univ, Dept Med, Baltimore, MD USA
[8] Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland Hts, OH USA
基金
美国国家卫生研究院;
关键词
antiretroviral therapy; cytokine; HIV; macrophage; monocyte; plasma; SOLUBLE CD163; INFECTED INDIVIDUALS; SMOOTHING PARAMETER; PREDICT MORTALITY; SEX-DIFFERENCES; PLASMA-LEVELS; INFLAMMATION; INTERLEUKIN-18; MONOCYTE; MARKERS;
D O I
10.1097/QAD.0000000000004033
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Although antiretroviral therapy (ART) suppresses viral replication and reduces inflammation, it does not lead to the normalization of cytokines. The long-term effects of ART beyond viral suppression have not been studied and are mostly limited to cross-sectional research. Design: The impact of long-term ART on the trajectory of 40 cytokines/chemokines in 31 men and 59 women who maintained viral suppression over a median period of 6 years (317 visits ranging from 24 to 384 weeks post ART initiation) were measured by Luminex. Methods: We used a generalized additive model with a Gaussian distribution and identity link function to model concentrations over time and investigate sex and race differences. Results: While most cytokine/chemokine trajectories remained stable, the trajectory of nine markers of monocyte/macrophage activation (IP-10, I-TAC, MIG, sCD163, sCD14, MCP-1, MIP-3 beta, CXCL13, TNF-alpha) decreased over time (adj. P < 0.05). Despite continuous viral suppression, M-CSF, IL-15, and LBP increased over time (adj. P < 0.05). sCD14 was the only cytokine whose trajectory differed by sex (adj. P = 0.033). Overall, women had lower mean levels of IL-18 but higher levels of sCD14 than did men (adj. P < 0.05). GRO alpha, LBP, and sCD14 showed significant differences between races (adj. P < 0.05). No association between cytokines and cellular HIV DNA/RNA was found. Conclusion: Our study reveals a continuous decline in markers of monocyte/macrophage activation over 6 years of suppressive ART, indicating that long-term treatment may mitigate inflammaging and cardiovascular-related outcomes. The higher levels of sCD14 observed in women are consistent with them having greater innate immune activation than men do.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [21] Long-term Outcomes of Patients With HIV and Pneumocystis jirovecii Pneumonia in the Antiretroviral Therapy Era
    Epling, Brian P.
    Manion, Maura
    Sirajuddin, Arlene
    Laidlaw, Elizabeth
    Galindo, Frances
    Anderson, Megan
    Roby, Gregg
    Rocco, Joseph M.
    Lisco, Andrea
    Sheikh, Virginia
    Kovacs, Joseph A.
    Sereti, Irini
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (08):
  • [22] Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy
    McManus, Hamish
    O'Connor, Catherine C.
    Boyd, Mark
    Broom, Jennifer
    Russell, Darren
    Watson, Kerrie
    Roth, Norman
    Read, Phillip J.
    Petoumenos, Kathy
    Law, Matthew G.
    PLOS ONE, 2012, 7 (11):
  • [23] Evaluating the long-term effects of combination antiretroviral therapy of HIV infection: a modeling study
    Cai, Jing
    Zhang, Jun
    Wang, Kai
    Dai, Zhixiang
    Hu, Zhiliang
    Dong, Yueping
    Peng, Zhihang
    JOURNAL OF MATHEMATICAL BIOLOGY, 2025, 90 (04)
  • [24] Predictors of long-term opioid use in HIV patients who initiated antiretroviral therapy
    Oh, Gyeon
    Brouwer, Emily S.
    Abner, Erin L.
    Fardo, David W.
    Freeman, Patricia R.
    Moga, Daniela C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 325 - 325
  • [25] Safety and Tolerability: Current Challenges to Antiretroviral Therapy for the Long-Term Management of HIV Infection
    Troya, Jesus
    Bascunana, Jose
    AIDS REVIEWS, 2016, 18 (03) : 127 - 137
  • [26] Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era
    King, JT
    Justice, AC
    Roberts, MS
    Chang, CCH
    MEDICAL DECISION MAKING, 2003, 23 (01) : 9 - 20
  • [27] Long-term effects of antiretroviral combination therapy on HIV type 1 DNA levels
    Aleman, S
    Visco-Comandini, U
    Loré, K
    Sönnerborg, A
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (14) : 1249 - 1254
  • [28] Factors associated with "short-term" and "long-term" adherence to antiretroviral therapy in patients with HIV/AIDS
    Mrus, JM
    Sherman, SN
    Ho, ML
    Hornung, RW
    Feinberg, J
    Fultz, SL
    Justice, AC
    Puchalski, CM
    Mandell, KL
    Tsevat, J
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 : 152 - 152
  • [29] Latent tuberculosis is associated with heightened levels of pro-and anti-inflammatory cytokines among Kenyan men and women living with HIV on long-term antiretroviral therapy
    Temu, Tecla M.
    Polyak, Stephen J.
    Wanjalla, Celestine N.
    Mandela, Nelson Aringo
    Dabee, Smritee
    Mogaka, Jerusha N.
    Masyuko, Sarah
    Longernecker, Chris
    Shakil, Saate
    Chohan, Bhavna
    Page, Stephanie T.
    Lacourse, Sylvia M.
    Gitura, Bernard
    Crothers, Kristina
    Oyugi, Julius
    Jaspan, Heather
    Farquhar, Carey
    Zifodya, Jerry S.
    AIDS, 2023, 37 (07) : 1065 - 1075
  • [30] Mortality Over Long-term Follow-up for People With HIV Receiving Longitudinal Care and Antiretroviral Therapy in Rural Haiti
    Richterman, Aaron
    Leandre, Fernet
    Jerome, J. Gregory
    Tsai, Alexander C.
    Ivers, Louise C.
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (08):